Abstract
Summary
Antibiotic JM-57h a wide spectrum agent, has been used to combat post-irradiation infection without significantly increasing the total number of survivors. In the group medicated daily an increase in the ST50 day was noted. The results obtained indicate that medication must be started during the first post-irradiation week before massive bacteremia occurs, otherwise such therapy will not be beneficial. At a dose of 0.1 of its LD50, antibiotic JM-57h was well tolerated and produced no fatalities or untoward reactions in CF-1 strain mice.
Get full access to this article
View all access options for this article.